ARVN (Arvinas, Inc)
Insider Trading Activity
Every open-market purchase and sale reported by ARVN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-26 | Linda Bain | Director | A | — | — |
| 2026-06-26 | Leslie V Norwalk | Director | A | — | — |
| 2026-06-26 | Everett Cunningham | Director | A | — | — |
| 2026-06-26 | Edward Moore Jr. Kennedy | Director | A | — | — |
| 2026-06-26 | Alsup Laurie Smaldone | Director | A | — | — |
| 2026-06-26 | Briggs Morrison | Director | A | — | — |
| 2026-06-24 | Andrew Saik | Chief Financial Officer | Sell | — | — |
| 2026-06-18 | Angela M Cacace | Chief Scientific Officer | Sell | — | — |
| 2026-05-22 | Randy Teel | President and CEO | Sell | — | — |
| 2026-05-13 | Randy Teel | President and CEO | Sell | — | — |
| 2026-05-13 | David K Loomis | VP, Chief Accounting Officer | Sell | — | — |
| 2026-05-13 | Noah Berkowitz | Chief Medical Officer | Sell | — | — |
| 2026-05-13 | Angela M Cacace | Chief Scientific Officer | Sell | — | — |
| 2026-05-13 | Andrew Saik | Chief Financial Officer | Sell | — | — |
| 2026-03-19 | Noah Berkowitz | Chief Medical Officer | Sell | — | — |
| 2026-03-12 | Randy Teel | President and CEO | A | — | — |
| 2026-03-09 | Briggs Morrison | Director | Buy | — | — |
| 2026-03-02 | Randy Teel | President and CEO | A | — | — |
| 2026-03-02 | Angela M Cacace | Chief Scientific Officer | A | — | — |
| 2026-03-02 | Noah Berkowitz | Chief Medical Officer | A | — | — |
| 2026-03-02 | Andrew Saik | Chief Financial Officer | A | — | — |
| 2026-03-02 | John G Houston | Director | Sell | — | — |
| 2026-03-02 | David K Loomis | VP, Chief Accounting Officer | A | — | — |
| 2026-02-25 | David K Loomis | Chief Accounting Officer | Sell | — | — |
| 2026-02-25 | Randy Teel | President and CEO | Sell | — | — |
| 2026-02-25 | Angela M Cacace | Chief Scientific Officer | Sell | — | — |
| 2026-02-18 | Andrew Saik | Chief Financial Officer | Sell | — | — |
| 2026-02-18 | Noah Berkowitz | Chief Medical Officer | Sell | — | — |
| 2026-02-18 | David K Loomis | Chief Accounting Officer | Sell | — | — |
| 2026-02-18 | Randy Teel | President and CEO | Sell | — | — |
| 2026-02-18 | Angela M Cacace | Chief Scientific Officer | Sell | — | — |
| 2025-11-07 | David K Loomis | Chief Accounting Officer | Sell | — | — |
| 2025-09-24 | Briggs Morrison | Director | Buy | — | — |
| 2025-06-30 | SUNIL AGARWAL | Director | A | — | — |
| 2025-06-27 | Linda Bain | Director | A | — | — |
| 2025-06-27 | Alsup Laurie Smaldone | Director | A | — | — |
| 2025-06-27 | JOHN D YOUNG | Director | A | — | — |
| 2025-06-27 | Briggs Morrison | Director | A | — | — |
| 2025-06-27 | Leslie V Norwalk | Director | A | — | — |
| 2025-06-27 | Everett Cunningham | Director | A | — | — |
| 2025-06-27 | Edward Moore Jr. Kennedy | Director | A | — | — |
| 2025-06-24 | Andrew Saik | Chief Financial Officer | Sell | — | — |
| 2025-06-18 | Angela M Cacace | Chief Scientific Officer | Sell | — | — |
| 2025-05-13 | Angela M Cacace | Chief Scientific Officer | A | — | — |
| 2025-05-13 | David K Loomis | Chief Accounting Officer | A | — | — |
| 2025-05-13 | Andrew Saik | Chief Financial Officer | A | — | — |
| 2025-05-13 | Noah Berkowitz | Chief Medical Officer | A | — | — |
| 2025-03-19 | Noah Berkowitz | Chief Medical Officer | Sell | — | — |
| 2025-02-25 | David K Loomis | Chief Accounting Officer | Sell | — | — |
| 2025-02-25 | Angela M Cacace | Chief Scientific Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,512,136 | — |
| — | 10%+ Owner | 3,989,554 | — |
| — | 10%+ Owner | 3,888,216 | — |
| — | 10%+ Owner | 3,589,554 | — |
| — | — | 3,138,412 | — |
| — | Director | 1,772,501 | — |
| — | Director | 1,694,351 | — |
| — | President and CEO | 1,152,792 | — |
| — | — | 767,623 | — |
| — | Director | 421,935 | — |
| — | 10%+ Owner | 307,078 | — |
| — | President and CEO | 285,009 | — |
| — | Chief Medical Officer | 191,395 | — |
| — | Chief Financial Officer | 187,432 | — |
| — | Chief Financial Officer | 181,916 | — |
| — | Chief Scientific Officer | 180,390 | — |
| — | President, R&D | 160,785 | — |
| — | Director | 111,548 | — |
| — | 10%+ Owner | 111,513 | — |
| — | Director | 84,290 | — |
| — | Director | 71,403 | — |
| — | Chief Medical Officer | 69,215 | — |
| — | Director | 41,572 | — |
| — | Director | 41,572 | — |
| — | Director | 41,572 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARVN quote page; the site-wide leaderboard is on the insider transactions hub.